Search
Kymera Therapeutics Inc
KYMRAdd to Watchlist
126.630USD
+4.030+3.29%
Close 10-30 16:00（ET）
10.53BMarket Cap
LossP/E TTM
Today
+3.29%
5 Days
+14.33%
1 Month
+13.27%
6 Months
+56.20%
Year to Date
+62.74%
1 Year
+104.77%
Key Figures
122.580Open
127.740High
120.51KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.14%Turnover Ratio
122.600Prev. Close
117.550Low
14.85MTurnover
LossP/E Static
6.98P/B
0.00%Div Yield TTM
-24.35%ROA
130.05052wk High
0.18Volume Ratio
-223.86MNet Profit
83.15MShares
-3.5766EPS TTM
2.03Beta
-27.09%ROE
55.66052wk Low
8.31%Amplitude
100.00%Gross Margin
10.53BMarket Cap
2.01Reward/Risk
3.93%Risk Rate
Kymera Therapeutics Inc's Score
0.03vs previous score
Forecast8.61
Financial Health8.65
Technical4.70
Valuation Dimensions9.36
Institutional Confidence10.00
Risk Assessment6.34
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
Kymera Therapeutics Inc Technical Analysis
Technical Indicators
Buy
Summary
Buy
Moving Average
Strong buy
Kymera Therapeutics Inc Latest Earnings Call Transcripts
Kymera Therapeutics (KYMR) Q3 2026 Earnings Call: KT-579 Data and KT-621 Readout Ahead
Kymera Therapeutics Q3 2026 earnings call highlights KT-579 Phase I IRF5 data, the upcoming KT-621 atopic dermatitis readout and runway into 2029.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-1.32/-1.27
Revenue / Forecast
0.00/3.05M
Kymera Therapeutics Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolKYMR
Number of employees188
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Baker Bros. Advisors LP | 10.52% |
| Fidelity Management & Research Company LLC | 10.47% |
| Avoro Capital Advisors LLC | 9.09% |
| T. Rowe Price Associates, Inc. | 7.41% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 46.54% |
| Investment Advisor/Hedge Fund | 28.92% |
| Hedge Fund | 25.81% |
| Venture Capital | 6.19% |
Related Instruments
+3.19%
-0.73%
+1.41%
+2.18%
-0.19%
+7.02%
+1.15%
+3.06%
+2.20%
+1.90%
+3.50%
+1.78%
+1.40%
+2.81%
+1.71%
+13.33%
-0.47%
+4.50%
-0.24%
-0.55%Popular Instruments
51788.900
-548.500 (-1.05%)
28406.600
-658.400 (-2.27%)
7583.100
-92.600 (-1.21%)
12785.000
-56.000 (-0.44%)
62328.000
-1656.000 (-2.59%)
6120.900
-77.700 (-1.25%)
102.428
+0.026 (+0.03%)
344.630
-4.280 (-1.23%)
204.640
-9.020 (-4.22%)
3874.710
-146.240 (-3.64%)
FAQs
What is the current price of Kymera Therapeutics Inc (KYMR)?
The current price of Kymera Therapeutics Inc (KYMR) is 126.63.
What is the symbol of Kymera Therapeutics Inc?
The ticker symbol of Kymera Therapeutics Inc is KYMR.
What is the 52-week high of Kymera Therapeutics Inc?
The 52-week high of Kymera Therapeutics Inc is 130.05.
What is the 52-week low of Kymera Therapeutics Inc?
The 52-week low of Kymera Therapeutics Inc is 55.66.
What is the market capitalization of Kymera Therapeutics Inc?
The market capitalization of Kymera Therapeutics Inc is 10.53B.
Is Kymera Therapeutics Inc (KYMR) currently rated as Buy, Hold, or Sell?
According to analysts, Kymera Therapeutics Inc (KYMR) has an overall rating of Buy, with a price target of 139.82.
What is the Earnings Per Share (EPS TTM) of Kymera Therapeutics Inc (KYMR)?
The Earnings Per Share (EPS TTM) of Kymera Therapeutics Inc (KYMR) is -3.58.